New Horizon Health and Proteomedix are joining forces for research purposes. The focus of this link-up will be on platforms and biomarkers used to treat cancer patients, further details of which can be found in a press release. As part of this partnership, New Horizon Health is investing a total of 3 million Swiss francs in the form of a convertible bond in Proteomedix.
Proteomedix is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH). The company has developed an innovative blood-based prostate cancer test by the name of Proclarix, which was launched on the European market in 2020. The company is headquartered at the Bio-Technopark Schlieren-Zurich.
The Chinese firm New Horizon Health specializes in developments in the field of cancer diagnosis and is listed on the Hong Kong Stock Exchange.
This is not the first China-based partnership that Proteomedix has agreed. For example, at the start of this year, the ETH spin-off entered into a cooperation with the Zhengzhou University Henan Cancer Hospital. Together, the two partners intend to clinically validate the efficacy of Proclarix.
Expand and grow your business globally with the Greater Zurich Area Ltd (GZA), the region’s official investment promotion agency. We provide support during the complex and dynamic process of taking a business global. Gaining a deep understanding of the target markets, local trends, the competition and the requirements are key to a successful expansion and global growth.